Autoantibodies, complement and type i interferon as biomarkers for personalized medicine in SLE

Lupus

Volumn 25, Issue 8, 2016, Pages 823-829

  Biesen, R ^a   Rose, T ^a   Hoyer, B F ^a   Alexander, T ^a   Hiepe, F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anti DNA antibodies; biomarker; companion diagnostics; complement components; Type I interferon

Indexed keywords

ANIFROLUMAB; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BELIMUMAB; BIOLOGICAL MARKER; COMPLEMENT; DOUBLE STRANDED DNA ANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERFERON; PLACEBO; PREDNISOLONE; PROTEASOME INHIBITOR; RONTALIZUMAB; SM ANTIBODY; THYMOCYTE ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; PERSONALIZED MEDICINE; PLASMA CELL; PLASMABLAST; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

AUTOANTIBODIES; BIOMARKERS; COMPLEMENT SYSTEM PROTEINS; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRECISION MEDICINE; SEVERITY OF ILLNESS INDEX;

EID: 84973327198     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316640922     Document Type: Article

References (65)

1. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL,. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8.
2. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y,. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Sem Arthritis Rheum 2004; 34: 501-537.
3. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeutics 2001; 69: 89-95.
4. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheu Dis 2012; 71: 1343-1349.
5. Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016; 75: 196-202.
6. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 2407-2415.
7. Yao Y, Higgs BW, Richman L, White B, Jallal B,. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: S6-S6.
8. Holborow EJ, Weir DM, Johnson GD,. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br Medical J 1957; 2: 732-734.
9. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A,. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 2007; 46: 1052-1056.
10. Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F,. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 2307-2315.
11. Amoura Z, Piette JC, Bach JF, Koutouzov S,. The key role of nucleosomes in lupus. Arthritis Rheum 1999; 42: 833-843.
12. Rubin RL,. Drug-induced lupus. Expert Opinion Drug Safety 2015; 14: 361-378.
13. Araujo-Fernandez S, Ahijon-Lana M, Isenberg DA,. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus 2014; 23: 545-553.
14. Biesen R, Dahnrich C, Rosemann A, et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R26-R26.
15. Barkhudarova F, Dahnrich C, Rosemann A, et al. Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R20-R20.
16. Bizzaro N, Villalta D, Giavarina D, Tozzoli R,. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012; 12: 97-106.
17. Suer W, Dahnrich C, Schlumberger W, Stocker W,. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J Autoimmun 2004; 22: 325-334.
18. Alba P, Bento L, Cuadrado MJ, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
19. Moroni G, Trendelenburg M, Del Papa N, et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490-498.
20. Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC,. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 851-856.
21. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA,. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1999; 42: 187-188.
22. Arnett FC, Reichlin M,. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995; 99: 465-472.
23. Ohira H, Takiguchi J, Rai T, et al. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res 2004; 28: 137-139.
24. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-992.
25. Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58: 843-853.
26. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
27. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194-1205.
28. Gladman DD, Ibanez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
29. Rose T, Grutzkau A, Hirseland H, et al. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 1639-1645.
30. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG,. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634-343-634-343.
31. Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098-3107.
32. Ho A, Magder LS, Barr SG, Petri M,. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-2349.
33. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
34. Ng KP, Manson JJ, Rahman A, Isenberg DA,. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55: 900-904.
35. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.
36. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 3623-3632.
37. Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015; 74: 1474-1478.
38. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A,. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011; 7: 170-178.
39. Jacobi AM, Mei H, Hoyer BF, et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 305-308.
40. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-5979.
41. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328-2337.
42. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214-223.
43. Belot A, Cimaz R,. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediat Rheumatol 2012; 10: 21-21.
44. Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 837-844.
45. Lange K, Wasserman E, Slobody LB,. The significance of serum complement levels for the diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus. Ann Internal Med 1960; 53: 636-646.
46. Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol 2015; 42: 2288-2295.
47. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3284-3290.
48. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Nat Acad Sci USA 2003; 100: 2610-2615.
49. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
50. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteom 2009; 1: 374312-374312.
51. Hua J, Kirou K, Lee C, Crow MK,. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-1916.
52. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 1136-1145.
53. Li Y, Lee PY, Kellner ES, et al. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R90-R90.
54. Trinchieri G,. Type I interferon: friend or foe? J Exp Med 2010; 207: 2053-2063.
55. Baechler EC, Batliwalla FM, Reed AM, et al. Gene expression profiling in human autoimmunity. Immunol Rev 2006; 210: 120-137.
56. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 141-151.
57. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-671.
58. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951-2962.
59. Luo N, Wu Y, Chen Y, et al. Upregulated BclG(L) expression enhances apoptosis of peripheral blood CD4+ T lymphocytes in patients with systemic lupus erythematosus. Clin Immunol 2009; 132: 349-361.
60. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T,. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992; 35: 417-422.
61. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 1440-1446.
62. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009; 18: 980-989.
63. Kong KO, Tan AW, Thong BY, et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 2009; 156: 134-140.
64. Kikuchi-Taura A, Yura A, Tsuji S, et al. Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus. Lupus 2015; 24: 1076-1080-1076-1080.
65. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R,. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.